AHU-377 CAS No.:149709-62-6
AHU-377 Usage： Used as pharmaceutical intermediate AHU-377 Packaging and Shipping： 25kg/ drum or as per buyer requirement. AHU-377 Storage: Ventilated and dry; separate from alkalis, oxidisers, o...
Category：Pharmaceutical Materials
Introduction
AHU-377 Usage： Used as pharmaceutical intermediate AHU-377 Packaging and Shipping： 25kg/ drum or as per buyer requirement. AHU-377 Storage: Ventilated and dry; separate from alkalis, oxidisers, organic materials and flammable materials
| Name | 4-(((2S,4R)-1-([1,1′-biphenyl]-4-yl)-5-ethoxy-4-methyl-5-oxopentan-2-yl)amino)-4-oxobutanoic acid |
| Synonyms | AHU-37 AHU377 AHU-377 AHU 377 SACUBITRIL AHU-377,149709-62-6 (2R,4S)-5-([1,1′-Biphenyl]-4-yl)-4-(3-carboxypropanamido)-2-methylpentanoic acid (2R,4S)-5-(Biphenyl-4-yl)-4-[(3-carboxypropionyl)amino]-2-methylpentanoic acid ethyl ester 4-(((2S,4R)-1-([1,1′-biphenyl]-4-yl)-5-ethoxy-4-methyl-5-oxopentan-2-yl)amino)-4-oxobutanoic acid 4-(((2R,4R)-1-([1,1′-biphenyl]-4-yl)-5-ethoxy-4-Methyl-5-oxopentan-2-yl)aMino)-4-oxobutanoic acid 4-(((2S,4R)-1-([1,1′-biphenyl]-4-yl)-5-ethoxy-4-Methyl-5-oxopentan-2-yl)aMino)-4-oxobutanoic acid |
| CAS | 149709-62-6 |
| EINECS | 1592732-453-0 |
| Molecular Formula | C24H29NO5 |
| Molar Mass | 411.49 |
| Density | 1.151±0.06 g/cm3(Predicted) |
| Boling Point | 656.9±55.0 °C(Predicted) |
| Solubility | 10 mM in DMSO |
| pKa | 4.72±0.10(Predicted) |
| Storage Condition | Sealed in dry,Store in freezer, under -20°C |
| Use | Intermediate |
| In vitro study | Sacubitril (AHU-377) is a single molecule that is comprised of molecular moieties of valsartan, an ARB, and Sacubitril (AHU-377), a neprilysin inhibitor (1:1 ratio). Sacubitril (AHU-377) is converted by enzymatic cleavage of the ethyl ester into the active neprilysin inhibiting metabolite LBQ657. The inactive NEPi precursor, Sacubitril (AHU-377), does not inhibit collagen accumulation in fibroblasts nor cardiac myocyte hypertrophy. In cardiac fibroblasts, the active NEPi LBQ657 had no discernible effects. In contrast, LBQ657 modestly inhibits cardiac myocyte hypertrophy. |
| In vivo study | In humans, Sacubitril (AHU-377) (t max 0.5-1.1 h) are absorbed quickly. Sacubitril (AHU-377) is converted rapidly into LBQ657 with its t max being reached in 1.9-3.5 h. Mean t 1/2 values for the biologically active LBQ657 is 9.9-11.1 h. In vehicle-treated dogs, ANF increases urinary sodium excretion from 17.3±3.6 to 199.5±18.4 pequivkglmin. This effect is potentiated significantly in animals which receive Sacubitril (AHU-377). Urinary volume is also potentiated in animals which receive an iv administration of Sacubitril (AHU-377). |
,Disclaimer: The above content is for reference and communication only among industry insiders, and does not guarantee its accuracy or completeness. According to relevant laws and regulations and the regulations of this website, units or individuals who purchase related items should obtain valid qualifications and qualification conditions.
